SGO Annual Meeting | Conference

Dr Coleman on Response Rates With Mirvetuximab Soravtansine in Ovarian Cancer

March 27th 2023

Robert L. Coleman, MD, FACOG, FACS, discusses an analysis of the phase 3 SORAYA trial evaluating response rates in patients with platinum-resistant ovarian cancer who received mirvetuximab soravtansine at different points in their disease course.

Dr Matulonis on Second-line Maintenance Therapy With Niraparib in Ovarian Cancer

March 27th 2023

Ursula A. Matulonis, MD, discusses final overall survival results from the phase 3 NOVA trial in patients with ovarian cancer.

Carolina Frailty Index Score Shows Utility in Ovarian Cancer Setting

March 27th 2023

Women with ovarian cancer may be effectively assessed for frailty status via the Carolina Frailty Index Score.

Olaparib Plus Selumetinib Produces Clinical Benefit in RAS-Mutated Ovarian and Endometrial Cancer

March 27th 2023

The recommended phase 2 dose of olaparib plus selumetinib generated a clinical benefit in patients with endometrial or ovarian cancer harboring RAS mutations, according to findings from the dose-expansion portion of the phase 1b SOLAR trial.

Post-Hoc Analysis Shows PFS Benefit of Maintenance Niraparib Not Affected by Dose Modifications in Ovarian Cancer

March 27th 2023

The use of an individualized starting dose and dose modifications due to treatment-emergent adverse effects did not impact the efficacy of maintenance niraparib in patients with newly diagnosed ovarian cancer, irrespective of BRCA mutation status.

Neoadjuvant Durvalumab/Tremelimumab Plus Chemo Meets PFS End Point in Advanced Ovarian Cancer

March 27th 2023

Neoadjuvant treatment with the combination of durvalumab plus tremelimumab and chemotherapy elicited a promising 12-month progression-free survival rate in patients with advanced-stage ovarian cancer.

Similar Total Scores Are Observed With GCLQ and LELSQ in Assessing Patients With Endometrial Cancer for Lymphedema

March 26th 2023

The gynecological cancer lymphedema questionnaire and the lower extremity lymphedema screening questionnaire showed moderate to substantial agreement across different cutoff points.

Long-Term HRQOL Remains Unimpaired With HIPEC Plus Cytoreductive Surgery in Newly Diagnosed Ovarian Cancer

March 26th 2023

Administration of hyperthermic intraperitoneal chemotherapy with cytoreductive surgery did not have a negative impact on health-related quality of life compared with cytoreductive surgery alone in patients with newly diagnosed ovarian cancer, according to findings from a phase 2 trial.

Dr. Mayadev on Atezolizumab Plus Chemoradiation in Locally Advanced Cervical Cancer

March 22nd 2022

Jyoti Mayadev, MD, discusses the phase 1 NRG-GY017 trial evaluating atezolizumab given as an immune primer or concurrently with extended field chemoradiation in patients with locally advanced, node-positive cervical cancer.

Dr. Slomovitz on the Key Objectives of the KEYNOTE-B21 Trial in High-Risk Endometrial Cancer

March 22nd 2022

Brian M. Slomovitz, discusses the phase 3 ENGOT-en11/GOG-3053/KEYNOTE-B21 trial.

Dr. Matulonis on the Results of the Phase 3 SORAYA Trial in Platinum-Resistant Ovarian Cancer

March 21st 2022

Ursula A. Matulonis, MD, discusses the results of the phase 3 SORAYA trial in platinum-resistant ovarian cancer.

Dr. Lara on Role of Molecular Differences in Disparities in Uterine Serous Carcinoma

March 21st 2022

Oliva Lara, MD, discusses the connection between molecular differences and disparities in cancer care in uterine serous carcinomas, as examined in a retrospective cohort study.

Maintenance Niraparib Given at Individualized Starting Dose Improves PFS in Ovarian Cancer

March 20th 2022

When maintenance niraparib was administered at an individualized starting dose, it resulted in a statistically significant and clinically meaningful improvement in progression-free survival vs placebo in patients with newly diagnosed ovarian cancer, irrespective of biomarker status.

Maintenance Selinexor Improves PFS Vs Placebo in Advanced or Recurrent Endometrial Cancer

March 20th 2022

Maintenance selinexor monotherapy was found to improve progression-free survival over placebo in patients with advanced or recurrent endometrial cancer.

IP Carboplatin/Paclitaxel Improves PFS, But Not OS, Vs IV Chemo in Ovarian Cancer

March 20th 2022

The use of intraperitoneal carboplatin with paclitaxel improved progression-free survival, but not overall survival, vs intravenous chemotherapy in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Mirvetuximab Soravtansine Elicits Encouraging ORR in FRα-High, Platinum-Resistant Ovarian Cancer

March 20th 2022

Mirvetuximab soravtansine was found to produce clinically meaningful antitumor activity with acceptable safety and tolerability in patients with platinum-resistant ovarian cancer and high folate receptor–alpha (FRα) expression.

Nemvaleukin Alfa/Pembrolizumab Combo Shows Promising Activity in Platinum-Resistant Ovarian Cancer

March 19th 2022

The combination of nemvaleukin alpha and pembrolizumab led to encouraging clinical activity in patients with pretreated ovarian cancer who are resistant to platinum-based chemotherapy.

Atezolizumab Plus Chemoradiation Triggers T-Cell Clonal Expansion in Locally Advanced Cervical Cancer

March 19th 2022

Atezolizumab given as an immune primer or concurrently with extended field chemoradiation demonstrated favorable progression-free survival and few dose-limiting toxicities, with evidence of T-cell clonal expansion in the tumors and peripheral blood of patients with locally advanced, node-positive cervical cancer.

Neoadjuvant Niraparib Shows Early Promise in BRCA-Mutated, HRD+ Ovarian Cancer

March 19th 2022

Neoadjuvant niraparib induced strong results for patients with BRCA-mutant, homologous repair deficient–positive advanced resectable ovarian cancer.

Niraparib Plus Bevacizumab Shows Promise in High-Risk Ovarian Cancer Population

March 19th 2022

Niraparib in combination with bevacizumab was efficacious following 1 line of platinum-based chemotherapy among patients with newly diagnosed advanced ovarian cancer, regardless of biomarker status.